Verition Fund Management LLC Acquires 100,454 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Verition Fund Management LLC grew its holdings in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 308.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 133,025 shares of the company’s stock after purchasing an additional 100,454 shares during the period. Verition Fund Management LLC owned approximately 0.25% of ALX Oncology worth $242,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Walleye Capital LLC boosted its holdings in ALX Oncology by 110.3% in the third quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after acquiring an additional 121,113 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of ALX Oncology by 207.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company’s stock worth $151,000 after purchasing an additional 56,028 shares during the last quarter. GSA Capital Partners LLP bought a new position in ALX Oncology in the 3rd quarter worth about $88,000. Los Angeles Capital Management LLC purchased a new stake in ALX Oncology during the 3rd quarter valued at about $469,000. Finally, Privium Fund Management B.V. raised its holdings in ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after buying an additional 112,093 shares during the last quarter. 97.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and a consensus price target of $10.67.

Insider Transactions at ALX Oncology

In related news, Director Rekha Hemrajani bought 30,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares of the company’s stock, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 33.40% of the company’s stock.

ALX Oncology Price Performance

NASDAQ ALXO opened at $1.45 on Monday. ALX Oncology Holdings Inc. has a one year low of $1.19 and a one year high of $17.83. The stock has a 50-day moving average of $1.48 and a 200 day moving average of $3.53. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The company has a market capitalization of $76.48 million, a price-to-earnings ratio of -0.49 and a beta of 1.04.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.